Genprex, Inc. · NASDAQ:GNPX

Genprex — Investor Presentation (March 2021)

46 slides from Genprex's investor presentation, March 2021

  1. Slide 1: Reprogramming the Course of Cancer and Diabetes

    REPROGRAMMING THE COURSE OF CANCER AND DIABETES NASDAQ: GNPX Updated March 2021 Nasdaq: GNPX 1

  2. Slide 2: Forward-Looking Statements

    FORWARD-LOOKING STATEMENTS Statements contained in this presentation regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual res

  3. Slide 3: GNPX at a Glance

    GNPX AT A GLANCE 10-DAY AVG SHARES COMPANY SYMBOL EXCHANGE SHARE PRICE1 MARKET CAP2 CASH3 VOLUME1 OUTSTANDING3 Genprex, Inc. GNPX Nasdaq $5.38 $254M 1.1M 47,276,764 $56,111,196 1: As of March 1, 2021. 2: Based on closing price as of March 1, 2021 and pro-forma shares outstanding as of February 11, 2

  4. Slide 4: Major Competitive Advantages

    MAJOR COMPETITIVE ADVANTAGES GENE THERAPY PLATFORM. Our non-viral Oncoprex® nanoparticle delivery system is designed to deliver a variety of therapeutic genes to fight cancer. Data indicate that our lead drug candidate, REQORSA™ immunogene therapy, may be combined with a number of approved cancer dr

  5. Slide 5: Executive Summary

    EXECUTIVE SUMMARY MAJOR COMPETITIVE ADVANTAGES • GENE THERAPY PLATFORM • DEMONSTRATED CLINICAL ACHIEVEMENT • FIRST SYSTEMIC GENE THERAPY • INITIATING TWO LUNG CANCER TRIALS USED FOR CANCER IN HUMANS IN 2021 • LARGE MARKETS AND UNMET NEED • WORLD-CLASS ACADEMIC PARTNERS • COMBINATION TRIALS WITH TOP

  6. Slide 6: Fast Track Designation

    FAST TRACK DESIGNATION Genprex received Fast Track Designation (FTD) for REQORSA + AstraZeneca’s Tagrisso for non-small cell lung cancer (NSCLC) patients that progressed on Tagrisso. Tagrisso had $4B+ worldwide gross sales in 2020, and it is AstraZeneca’s highest grossing product. FTD is for therapi

  7. Slide 7: Research and Development Pipeline

    RESEARCH AND DEVELOPMENT PIPELINE Nasdaq: GNPX 7

  8. Slide 8: Phase 2 General Study Characteristics

    GENERAL STUDY CHARACTERISTICS ● REQORSA in combination with AstraZeneca’s Tagrisso for NSCLC ● Patients with Stage 4, EGFR mutant NSCLC whose disease progressed after Tagrisso ● ~15 U.S. sites ~92 patients PASE 1 ● ○ Phase 1: 9-18 patients ○ Phase 2: 74 patients • Interim analysis at 51 events (i.e.

  9. Slide 9: Study Components and Endpoints

    COMPONENT PRIMARY ENDPOINT 3+3 dose escalation of PHASE 1 ● ● Dose limiting toxicity REQORSA in combination with Tagrisso PRIMARY ENDPOINT SECONDARY ENDPOINTS COMPONENT Progression free survival (PFS) ● Overall response rate Randomized 1:1, open-label, ● PHASE 2 ● PFS improvement of REQORSA combinat

  10. Slide 10: Bridging Gaps in Modern Medicine

    BRIDGING GAPS IN MODERN MEDICINE HELPING PATIENTS WITH LIMITED TREATMENT OPTIONS ONCOLOGY DIABETES ● Genprex’s oncology combination treatment ● Gene therapy drug candidate addresses Type 1 and approach utilizes targeted therapies and Type 2 diabetes. immunotherapies. ● May reduce or eliminate daily

  11. Slide 11: Oncology Program

    ONCOLOGY PROGRAM Nasdaq: GNPX 11

  12. Slide 12: Non-Small Cell Lung Cancer Market Statistics

    NON-SMALL CELL LUNG CANCER MARKET STATISTICS 84% MOST COMMON LUNG CANCER NSCLC represents the majority of all lung cancers. $4B+ TAGRISSO® 2020 SALES AstraZeneca’s highest grossing product. 2M WORLDWIDE CASES More than two million cases per year worldwide. $14B+ KEYTRUDA® 2020 SALES Merck’s highest

  13. Slide 13: Novel Platform to Treat Cancer

    NOVEL PLATFORM TO TREAT CANCER ONCOPREX® NANOPARTICLE DELIVERY SYSTEM GENES Multiple tumor SYNERGIES suppressor genes Modern approach using combination therapy CANCERS Genetic mutations found in other cancers Nasdaq: GNPX 13

  14. Slide 14: Oncoprex Nanoparticle Delivery System

    ONCOPREX NANOPARTICLE DELIVERY SYSTEM CATIONIC LIPID NANOPARTICLE CARRIES DRUG TO TUMORS Our non-viral, biodegradable, positively-charged lipid nanoparticle (LNP) has affinity to negatively-charged cancer cells, with up to a 33-fold uptake in cancer cells vs. normal cells and has been well tolerated

  15. Slide 15: Targeting Negative Surface Charges of Cancer Cells

    TARGETING NEGATIVE SURFACE CHARGES OF CANCER CELLS AN IDEAL MEANS TO SELECTIVELY TARGET CANCER CELLS • The activities of glucose metabolism have a profound impact on the surface of cancer cells • Elevated glycolysis in cancer cells lead to a higher secretion of lactate • Secreted lactate ions remove

  16. Slide 16: REQORSA Targets Cancer at Its Core

    REQORSA™ TARGETS CANCER AT ITS CORE DOTAP: CHOL-TUSC2 CONTROLS CELL SIGNALING STIMULATES APOPTOTIC PATHWAYS MODULATES IMMUNE RESPONSE Pan-kinase inhibition decreases cell Leads to programmed cell death Promotes immune activity against proliferation cancer Nasdaq: GNPX 16

  17. Slide 17: TUSC2 Inhibits Key Cell Signaling

    TUSC2 INHIBITS KEY CELL SIGNALING TUSC2 TUMOR SUPPRESSOR GENE HAS PAN-KINASE ACTIVITY THAT CAN OVERCOME CANCER RESISTANCE PATHWAYS Nasdaq: GNPX 17

  18. Slide 18: REQORSA Modulates the Immune System

    REQORSA MODULATES THE IMMUNE SYSTEM A B C Immunomodulation of Carbo + Pembro + TUSC2 demonstrates rationale for the Acclaim-1 and Acclaim-2 clinical trials treating patients who show progression after treatment with Tagrisso or Keytruda. D E Note: Treg and Myeloid cells are immunosuppressive Image:

  19. Slide 19: REQORSA Monotherapy

    REQORSA MONOTHERAPY ONC-001 TRIAL DOSE ESCALATION STUDY Explore toxicity and tolerability in patients. Phase 1 monotherapy results: ● 31 Stage IV patients with at least 1 of 6 trial doses ● 23 patients evaluable ● Cancer growth halted in 5 of 23 patients ● Stable disease n=5; responses n=3 ● Maximum

  20. Slide 20: REQORSA + Tarceva Combination

    REQORSA + TARCEVA COMBINATION PHASE 2 PRELIMINARY DATA IN SUBJECTS WITH OR WITHOUT EGFR MUTATIONS LINE OF PATIENT EGFR STATUS RESPONSE PRIOR THERAPY THERAPY Positive (exon 18+20) Complete Response Chemo 3 Negative 24% regression Target Lesion Chemo / anti-PD1 2 30% regression one Target Lesion Negat

  21. Slide 21: REQORSA + Tarceva Combination

    REQORSA + TARCEVA COMBINATION Nasdaq: GNPX 21

  22. Slide 22: REQORSA Shows Synergy with Immunotherapies

    REQORSA SHOWS SYNERGY WITH IMMUNOTHERAPIES REQORSA IS SYNERGISTIC WITH ANTI-PD1 IN A SYNGENEIC MOUSE MODEL OF LUNG CANCER TUSC2+anti-PD1 combination significantly prolonged TUSC2+anti-PD1 exhibit greater antitumor activity than survival in a lung metastasis model refractory to either agent alone or

  23. Slide 23: REQORSA Shows Synergy with Immunotherapies

    REQORSA SHOWS SYNERGY WITH IMMUNOTHERAPIES REQORSA IS SYNERGISTIC WITH ANTI-PD1 IN A HUMANIZED MOUSE MODEL OF LUNG CANCER REQORSA + Keytruda REQORSA + Keytruda + Chemo Strong antitumor immune responses of anti-PD1 were REQORSA+anti-PD1+chemo combination resulted found against PDX tumors developed in

  24. Slide 24: Diabetes Program

    DIABETES PROGRAM Nasdaq: GNPX 24

  25. Slide 25: Diabetic Patients in Need of Modern Therapy

    DIABETIC PATIENTS IN NEED OF MODERN THERAPY GPX-002 MAY ELIMINATE NEED FOR INSULIN IN DIABETIC PATIENTS Type 1 and Type 2 diabetes affect approximately 34 million people in the U.S1, or 10 percent of the U.S. population. May replace daily burden of blood glucose monitoring and insulin replacement th

  26. Slide 26: GPX-002 Replenishes Levels of Insulin

    GPX-002 REPLENISHES LEVELS OF INSULIN REPROGRAMS AND RESTORES CELL FUNCTION Novel infusion process uses an endoscope and an AAV vector to deliver the Pdx1 and MafA genes to the pancreas. Transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but are distinc

  27. Slide 27: Key Milestones Through 2021 & Beyond

    KEY MILESTONES THROUGH 2021 & BEYOND Nasdaq: GNPX 27

  28. Slide 28: Some Targeted Therapy Company Valuations

    SOME TARGETED THERAPY COMPANY VALUATIONS DRUG COMPANY SYMBOL EXCHANGE INDICATION PHASE VALUATION CANDIDATE/TARGET Melanoma, Head and Neck, Iovance IOVA Nasdaq Cervical, NSCLC, Chronic Lifileucel, LN-145 Phase 3(1,2) $5.7 Billion Biotherapeutics Lymphocytic Leukemia NSCLC, Colorectal, Renal Mirati Th

  29. Slide 29: Meet Our Team

    MEET OUR TEAM COMPANY MANAGEMENT RODNEY VARNER, JD CATHERINE VACZY Chairman, President & Chief Executive Officer Executive VP, General Counsel & Chief Strategy Officer • 30+ years of expertise in corporate law, including corporate governance, in biotech industry • 20+ years of experience in senior e

  30. Slide 30: Meet Our Team

    MEET OUR TEAM COMPANY MANAGEMENT THOMAS GALLAGHER, JD WILLIAM GANNON, JR., MD MBA Senior Vice President, Intellectual Property Vice President of Regulatory Affairs and Licensing • 30+ years of experience in biotech and pharma • 20+ years of expertise in biotech IP law, business regulatory affairs an

  31. Slide 31: Scientific Advisory Board

    MEET OUR TEAM SCIENTIFIC ADVISORY BOARD PASI ANTERO JÄNNE JACK A. ROTH MD, PhD • Professor of Medicine, Harvard Medical School; MD, FACS, Chairman Director of Dana Farber Cancer Institute Lowe Center • Professor and Bud Johnson Distinguished Clinical for Thoracic Oncology; Scientific Director of the

  32. Slide 32: Clinical Advisory Board

    MEET OUR TEAM CLINICAL ADVISORY BOARD COL. GEORGE PEOPLES MICHAEL MORSE MD, FACS MD, MHS, FACP • Professor of Medicine, Division of Medical Oncology • Chief Executive Officer of Cancer Insight, LLC, a in the Department of Surgery at Duke University boutique cancer immunotherapy CRO • Research expert

  33. Slide 33: Board of Directors

    MEET OUR TEAM BOARD OF DIRECTORS RODNEY VARNER, JD Chairman of the Board BRENT LONGNECKER • 30+ years of expertise in corporate law, including Board Director corporate governance, in biotech industry • Former owner of securities broker dealer firm • Chief Executive Officer, Longnecker & Associates •

  34. Slide 34: 21st Century Gene Therapies

    21ST CENTURY GENE THERAPIES WE BELIEVE LARGE MARKETS AND UNMET NEED IN A FUTURE OF COMBINATION TRIALS WITH TOP TRANSFORMATIONAL SELLING DRUGS FAST TRACK DESIGNATION PATIENT CARE EXPLORING NEW INDICATIONS AND PARTNERSHIPS Nasdaq: GNPX 34

  35. Slide 35: Contact

    NASDAQ: GNPX 1601 Trinity St, Bldg B, #3.312.09, Austin, Texas 78712 (877) 774 - GNPX | investors@genprex.com Nasdaq: GNPX

  36. Slide 36: Appendix

    APPENDIX Nasdaq: GNPX 36

  37. Slide 37: Preparing to Initiate Two New Combination Clinical Trials

    PREPARING TO INITIATE TWO NEW COMBINATION CLINICAL TRIALS ONCOPREX® Nanoparticle Delivery System is the lipid nanoparticle delivery system used in REQORSA™. Nasdaq: GNPX 37

  38. Slide 38: Effects of Genetic Alterations in Suppressor Genes

    EFFECTS OF GENETIC ALTERATIONS IN SUPPRESSOR GENES The most common genetic alterations present in NSCLC are located in tumor-suppressor genes against which no targeted agents have been developed. ● Regulation of Malignant Tumor Growth ● Insensitivity to Growth-inhibitory Signals ● Evasions of Progra

  39. Slide 39: Why Systemic Gene Therapy?

    WHY SYSTEMIC GENE THERAPY? ● Lipid nanoparticles have been shown to encapsulate plasmid DNA, which allows the delivery of gene therapeutic agents intravenously to distant metastases ● Lipid nanoparticles with TUSC2 have up to a 33-fold affinity for cancer cells compared to healthy cells ● No need to

  40. Slide 40: Why TUSC2?

    WHY TUSC2? ● 80% of all lung cancer cells lack the TUSC2 tumor suppressor gene ● Loss or reduction of TUSC2 expression is associated with significantly worse overall survival ● Premalignant lesions express significantly lower levels of TUSC2 compared with normal bronchial epithelia Nasdaq: GNPX 40

  41. Slide 41: Viral vs. Non-Viral Vectors

    VIRAL VS. NON-VIRAL VECTORS The most common viral vectors are adenoviruses and retroviruses ● High level of transfection efficiency ● Generally stable ● Less specificity of target cells ● Can be immunogenic because capsid and viral proteins cause inflammation ● Reported cases of death and causing le

  42. Slide 42: Other Potential Cancer Indications

    OTHER POTENTIAL CANCER INDICATIONS The region of the TUSC2 tumor suppressor gene is associated with chromosome 3p. In addition to NSCLC, other potential indications include: ● Thyroid ● Renal ● Breast ● Head & Neck ● Mesothelioma ● Ovary Ivanova, A.V., Ivanov, S.V., Prudkin, L. et al. Mechanisms of

  43. Slide 43: REQORSA + Tagrisso Reduce Tumor Growth

    REQORSA + TAGRISSO REDUCE TUMOR GROWTH Osimertinib is the generic form of Tagrisso. Nasdaq: GNPX 43

  44. Slide 44: REQORSA + Tagrisso Reduce Tumor Growth

    REQORSA + TAGRISSO REDUCE TUMOR GROWTH EFFECT OF TAGRISSO (OSIMERTINIB) + TUSC2 ON A549-LUC METASTASIS ON NSG MICE Osimertinib is the generic form of Tagrisso. Nasdaq: GNPX 44

  45. Slide 45: Effect of REQORSA + Carbo + Keytruda on Humanized A549 Lung Metastasis Model

    EFFECT OF REQORSA + CARBO + KEYTRUDA ON HUMANIZED A549 LUNG METASTASIS MODEL Effect of Carbo+Pembro+TUSC2 on A549 lung met on Hu-NSG 60000 **** % of change (wk2 vs wk5) 40000 tumor intensity 20000 *** 8000 *** 6000 4000 2000 0 2 t o 2 en SC SC br tm em TU TU ea +P o+ tr bo br o N em ar C +P bo ar C

  46. Slide 46: Effect of REQORSA + Carbo + Keytruda on Humanized A549 Lung Metastasis Model

    EFFECT OF REQORSA + CARBO + KEYTRUDA ON HUMANIZED A549 LUNG METASTASIS MODEL Effect of Carbo+Pembro+TUSC2 on A549 lung met on Hu-NSG 6×10 9 No treatment TUSC2 4×10 9 Carbo+Pembro Total Flux [p/s] Carbo+Pembro+TUSC2 2×10 9 2×10 8 1.5×10 8 1×10 8 *** 5×10 7 ** * 0 D14 D28 D35 *** p= 0.0003 vs No treat

Genprex — Investor Presentation (March 2021) on 6ix